Trial Profile
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs BMS 690514 (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 28 Apr 2012 Planned number of patients changed from 140 to 188 as reported by European Clinical Trials Database record.
- 08 Mar 2011 Planned End Date changed from 1 Oct 2011 to 1 Apr 2012 as reported by ClinicalTrials.gov.
- 08 Mar 2011 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.